The vaccine against human papillomavirus (HPV), the sexually transmitted virus that causes cervical cancer, will be most cost-effective in the U.S. with universal vaccination of 12-year-old girls and catch-up efforts to vaccinate girls and women ages 13 to 21, researchers say.